Tagged with r&d

Canada David Main, CEO and president of Aquinox Pharmaceuticals Inc., introduces the company he founded in 2006, which now is in the late stages of development of a drug targeting the SHIP1 enzyme, with a focus on treating interstitial cystitis/bladder pain syndrome. Other applications may include blood cancers and chronic prostatitis/chronic…

Poland Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the first ever CDK8 inhibitor for acute myeloid leukaemia with great opportunities for further indications and development. Furthermore, he highlights the…

Brazil Prof. Dr. Luiz Calistro Balestrassi, founder and president of NEUROTEC® – Biomedical Research & Development Company from Itajubá-MG, Brazil, and his daughter Esperança Balestrassi, Neurotec´s executive director, discuss the past, present, and future challenges of this pioneering medical device company that started in 1985. In this interview, Dr. Balestrassi –…

Switzerland Karen Huebscher, CEO of Solvias, a Swiss-headquartered world leader in contract research, development and manufacturing, explains her decision to join the company after a distinguished career at Novartis, the evolution of pharmaceutical client demands, and Solvias’s evolving international footprint. After more than 15 years with Switzerland’s largest life sciences group…

Canada Dr. David Goodman, CEO of Pharmascience, talks about the strategy for the international expansion of the company, key for which are long-lasting partnerships. He also analyzes the re-organization of the company amongst the two main axes of generics and branded products and highlights its dedication to R&D, especially in the…

Canada Stephen Thompson affirms Baxter’s 80-year commitment to Canada, and describes the benefits of having a local manufacturing presence. He further discusses the company’s latest innovations, notably in renal care and telehealth solutions. Baxter is celebrating 80 years in Canada this year. What is the strategic importance of Canada for Baxter’s…

Switzerland Laurent-Dominique Piveteau, CEO of Swiss medtech innovator Debiotech, discusses digital disruption, Swiss innovation, and future growth drivers. As well as being CEO of Debiotech, you also lecture courses at EPFL on “Economics of Innovation in the Biomedical Industry”. What are your thoughts on the incorporation of disruptive technologies in the…

Brazil Cesar Rengifo, senior vice president and area director Emerging Markets West at GSK, the fastest growing multinational company in both Brazil and Latin America, discusses the perfect match between GSK’s product portfolio and the region’s healthcare needs as well as the opportunities it entails for the company and Latin America’s…

Poland Jarek Oleszczuk, country president of AstraZeneca Poland, the leading R&D investor in Poland, discusses the exciting milestones that the company has achieved, including reimbursement of two breakthrough oncology therapies, as well as the company’s addition of 500 staff, representing now a 1,150-strong workforce. Furthermore, he touches on AstraZeneca’s key role…

Switzerland Jeff Dufour, country manager Switzerland and BU lead Internal Medicine at Pfizer, discusses his first impressions of the country, his priorities for greater dialogue with Swiss healthcare insurers, and Switzerland’s potential as a ‘test market’ for the company. Can you give our international readers an outline of your background and…

Canada Marc LePage, president and CEO of Genome Canada describes the early days of the organization and talks modern day plans, such as personalized diagnostics for rare diseases, international alliances and genomic data collection and sharing.   Marc, you helped pioneer the creation of Genome in 2000 and led Génome Québec…

Canada Dr. John Sampalis, CEO of JSS talks about the impact that changes in the global R&D landscape have had on JSS, the role technology is playing in running an efficient clinical trial program and the company’s next exciting move into the US. John, what have been the main milestones of…